mRNA Vaccines and Therapeutics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2021-26

1
Global mRNA Vaccines and Therapeutics Market
Research and Forecast Report 2021-2026




Author Elena Anderson, Marketing Manager
IMARC Group
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2019 IMARC All Rights Reserved
2
About IMARC Group
Report Description
The International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all sectors
and regions to identify their highest-value
opportunities, address their most critical
challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global mRNA Vaccines and Therapeutics Market
Research Report According to the latest report
by IMARC Group, titled "mRNA Vaccines and
Therapeutics Market Global Industry Trends,
Share, Size, Growth, Opportunity and Forecast
2021-2026," the global mRNA vaccines and
therapeutics market size is expected to reach US
9.41 Billion in 2021. Messenger Ribonucleic
Acid (mRNA) is a single-stranded RNA molecule
that plays a vital role in human biology,
especially in protein synthesis. Numerous mRNA
vaccines and therapeutics are now available in
the market that are administered in the human
body to trigger virus-detecting immune sensors.
This is executed to induce the production of
antibodies that further bind to the potential
pathogens. These solutions use genetic
information to produce viral antigen proteins
within the cells and provide acquired immunity
through an RNA containing vector, such as lipid
nanoparticles. Their use aids in boosting the
immunity of the body by improving B- and T-cell
responses. Request Free Sample Report
https//www.imarcgroup.com/mrna-vaccines-therapeut
ics-market/requestsample
4
Report Description and Highlights
Report Description
Global mRNA Vaccines and Therapeutics Market
Trends mRNA vaccines represent a promising
alternative to conventional vaccines due to their
high potency, capacity for rapid development and
potential for low-cost manufacture. Along with
this, there has been a rise in the requirement of
vaccines and therapeutics for the treatment of
various viral infections, such as Ebola and Human
Immunodeficiency Virus (HIV). Since these
therapeutics are considered to be more effective
against pathogens due to their enhanced
immunogenicity, numerous private and public
companies are heavily investing in extensive
research and development (RD) activities in the
field of biotechnology for vaccine development
and protein replacement therapy using mRNA.
Additionally, on account of the outbreak of the
coronavirus disease (COVID-19) pandemic, numerous
companies are currently engaging in the
development of a vaccine to curb the transmission
of the virus, thereby creating a positive outlook
for the market. Moderna, Inc. is one such
leading mRNA technology firm that is actively
invested in the development of the mRNA-1273
vaccine against the novel coronavirus
(SARS-CoV-2). It has registered positive interim
results in its Phase 1 study and has already
proceeded with the Phase 3 study of mRNA-1273
that is being conducted in collaboration with the
NIH and BARDA. The market is further driven by
the significant improvements in the lipid
nanoparticle formulations for in-vivo systemic
delivery of mRNA. On account of the
aforementioned factors, the market is anticipated
to register a CAGR of 10.5 during 2021-2026,
reaching a value of US 15.49 Billion by 2026.

5
Report Description and Highlights
Report Description

• Market Summary
• Breakup by Vaccine Type
• Self-amplifying mRNA-based Vaccines
• Conventional Non-Amplifying mRNA-Based Vaccines
•  
• Breakup by Treatment Type
• Bioengineered Vaccine
• Gene Therapy 
• Gene Transcription 
• Cell Therapy
• Monoclonal Antibody
• Others
• Breakup by Vaccine Manufacturing
• In-House
• Out-Sourced

6
Report Description and Highlights
Report Description

• Breakup by Application
• Cancer
• Infectious Disease
• Gene Editing
• Protein Replacement
• Breakup by End-User
• Hospitals and Clinics
• Research Organizations
• Others
• Breakup by Region
• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India

7
Report Description and Highlights
Report Description

• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Argentina
• Columbia
• Chile
• Peru
• Others

8
Report Description and Highlights
Report Description

• Middle East and Africa Turkey
• Saudi Arabia
• Iran
• United Arab Emirates
• Others
• Competitive Landscape with Key Players
• Arcturus Therapeutics Inc.
• BioNTech SE
• CureVac AG
• Etherna
• ethris GmbH
• GlaxoSmithKline PLC
• Moderna Therapeutics Inc.
• Translate Bio Inc.
• Argos Therapeutics, Inc.
• Sangamo Therapeutics Inc.
• Pfizer Inc

9
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
10
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
11
Report Description and Highlights
Report Description

2019 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
12

Contact Us